How We’re Mobilizing Our Resources to Help Find Solutions for Covid-19
Learn More
Press Release Archive
-
Johnson & Johnson Postpones 2020 Medical Devices Business Review Due to the CoronavirusJohnson & Johnson Postpones 2020 Medical Devices Business Review Due to the Coronavirus
-
Johnson & Johnson to Host Virtual Annual Meeting of ShareholdersJohnson & Johnson to Host Virtual Annual Meeting of Shareholders
-
Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic UseJohnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic UseJohnson & Johnson and BARDA Together Commit More than $1 Billion to Novel Coronavirus Vaccine Research and Development; Company Expects to Initiate Phase 1 Human Clinical Studies of Vaccine Candidate at Latest by September 2020Johnson & Johnson Will Establish New U.S. Vaccine Manufacturing Capabilities and Additional Production Capacity Outside the U.S. to Begin Production at Risk to Help Ensure Global Vaccine Supply
-
Landmark Phase 3 VOYAGER PAD Study of XARELTO® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity RevascularizationLandmark Phase 3 VOYAGER PAD Study of XARELTO® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity RevascularizationXARELTO® has the potential to be the first anticoagulant in 20 years[i] to show a benefit in these high-risk patientsTwo major Phase 3 trials have evaluated XARELTO® vascular dose plus aspirin in treating patients with atherosclerotic disease
-
Janssen Announces Health Canada Approval of CABENUVA™, the First Long-Acting Regimen for the Treatment of HIVJanssen Announces Health Canada Approval of CABENUVA™, the First Long-Acting Regimen for the Treatment of HIVCABENUVA™ offers adults living with HIV a new once-monthly injectable option for maintaining viral suppression
-
Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific SessionJanssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific SessionHighlights include four late-breaking XARELTO® (rivaroxaban) abstractsFour INVOKANA® (canagliflozin) abstracts from the pivotal CREDENCE study will also be presented
-
Lack of evidence to support use of darunavir-based treatments for SARS-CoV-2Lack of evidence to support use of darunavir-based treatments for SARS-CoV-2
-
Johnson & Johnson Announces Collaboration with the Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine DevelopmentJohnson & Johnson Announces Collaboration with the Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine DevelopmentResearch well underway as Janssen scientists collaborate with leading virology laboratory led by Dan Barouch, M.D., Ph.D.
-
Johnson & Johnson Business Continuity Statement (3/27)Johnson & Johnson Business Continuity Statement (3/27)
-
Janssen Announces Results of Phase 3 Study Demonstrating the Safety and Efficacy of Long-Acting Injectable HIV Treatment Regimen of Rilpivirine And Cabotegravir through 96 WeeksJanssen Announces Results of Phase 3 Study Demonstrating the Safety and Efficacy of Long-Acting Injectable HIV Treatment Regimen of Rilpivirine And Cabotegravir through 96 WeeksFLAIR Phase 3 study demonstrated patient satisfaction and preference for the long-acting injectable regimen over daily oral therapy